ReviewCardiac failure review2022
Polypharmacy in Older People With Heart Failure: Roles of the Geriatrician and Pharmacist.
Review in Cardiac failure review, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.
- Cardiovascular risk associated with polypharmacy in heart failure: a systematic review and meta-analysis.ESC heart failure · 2026Pooled it
- Development and Validation of an XGBoost-SHAP Model for Predicting Adverse Outcomes in Elderly Cardiovascular Patients With Polypharmacy: A Retrospective Cohort Study.Pharmacology research & perspectives · 2026Article
- Health-related quality of life and six-month hospitalization in older outpatients with heart failure with reduced ejection fraction: a prospective observational study.Health and quality of life outcomes · 2026Observational
- How to handle polypharmacy in heart failure. A clinical consensus statement of the Heart Failure Association of the ESC.European journal of heart failure · 2025Review
- Contextual Factors Affecting Adherence Revealed by Old Patients with Heart Failure in Hospital and Primary Care Interactions: A Descriptive Study.Patient preference and adherence · 2025Article
- An Observational Study of Evidence-Based Therapies in Older Patients with Heart Failure with Reduced Ejection Fraction: Insights from a Dedicated Heart Failure Clinic.Journal of clinical medicine · 2024Article
- Multitarget Pharmacology of Sulfur-Nitrogen Heterocycles: Anticancer and Antioxidant Perspectives.Antioxidants (Basel, Switzerland) · 2024Review
- Definition of Polypharmacy in Heart Failure: A Scoping Review of the Literature.Cardiology research · 2024Article
- What is the association of polypharmacy with frailty in heart failure? A systematic review and meta-analysis.Journal of frailty, sarcopenia and falls · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure (HF) is a common health condition that typically affects older adults. Many people with HF are cared for on an inpatient basis, by noncardiologists, such as acute medical physicians, geriatricians and other physicians. Treatment options for HF are ever increasing, and adherence to guidelines for prognostic therapy contributes to polypharmacy, which is very familiar to clinicians who care for older people. This article explores the recent trials in both HF with reduced ejection fraction and HF with preserved ejection fraction and the limitations of international guidance in their management with respect to older people. In addition, this article discusses the challenge of managing polypharmacy in those with advanced age, and the importance of involving a geriatrician and pharmacist in the HF multidisciplinary team to provide a holistic and person-centred approach to optimisation of HF therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.